TY - JOUR T1 - Quarantine, relaxation and mutation explaining the CoViD-19 epidemic in São Paulo State (Brazil) JF - medRxiv DO - 10.1101/2021.04.12.21255325 SP - 2021.04.12.21255325 AU - Hyun Mo Yang AU - Luis Pedro Lombardi Junior AU - Fabio Fernandes Morato Castro AU - Ariana Campos Yang Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/15/2021.04.12.21255325.abstract N2 - Background The continuous SARS-CoV-2 transmission in several countries could contribute to the mutations’ appearance. The circulation of more virulent variants may increase the number of severe CoViD-19 needing hospital care and fatalities hugely.Methods The partial quarantine in São Paulo State and further relaxation associated with the mutations are explained by a mathematical model based on the CoViD-19 natural history encompassing the age-dependent fatality. The model parameters were fitted considering the observed data from São Paulo State.Results The partial quarantine was explained by the less virulent SARS-CoV-2 transmission, but the relaxation alone could not explain the epidemic observed in São Paulo State. However, more virulent variants plus the transmission among isolated individuals explained the increased CoViD-19 fatalities.Conclusions The model described the CoViD-19 epidemic in São Paulo State by considering the partial quarantine, relaxation and mutations. The model provided a potential epidemiological scenario in the absence of mass vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available at Health ministry site https://covid.saude.gov.br/ ER -